NanoString’s Future is Secured!

Letter from Our CEO — March 11, 2024

Dear Customers, Scientists, and Partners,

I am writing to update you on two critical developments at NanoString that will secure the future of our company and provide customers continued access to our platforms for years to come.

First, we recently won a major victory in our ongoing patent litigation with 10x Genomics. On February 26, 2024, the highest patent court in Europe – the Unified Patent Court (“UPC”) Court of Appeal – overturned a preliminary injunction that had impacted the sale of the CosMx™ Spatial Molecular Imager (SMI) products in the EU. Following an in-depth analysis of the validity of the patent at issue, the court found that it is likely that the 10x Genomics/Harvard patent is invalid on the basis of prior art. 

NanoString has resumed marketing and sales of all CosMx SMI products across 16 European countries. We believe this victory in Europe is a turning point for NanoString and the field of spatial biology, as the same prior art that was relied upon by the UPC Court of Appeal in its decision will be presented at our United States trial where similar legal questions will be considered.

Second, on March 10, 2024, leading life sciences investment firm Patient Square Capital (“Patient Square”) agreed to purchase NanoString with a plan, upon approval of the bankruptcy court, to take the company private and continue its business and operations. This agreement with Patient Square represents an important step in our financial restructuring. 

Silicon Valley-based Patient Square has approximately $8 billion in assets under management, and upon closing  the transaction, NanoString will join Patient Square’s portfolio of eleven other companies focused on therapeutics, medical technology, and health services. Patient Square was attracted to NanoString for our technology portfolio, great people, and track record of serving customers in the scientific research community. We believe that Patient Square is committed to continuing NanoString’s mission to Map the Universe of Biology and is prepared to invest in our market-leading product roadmap.

Together, our victory in the European court and the agreement with Patient Square provides continuity for our customers and employees, ensuring that our leading-edge platforms for spatial biology and gene expression will be available for many years to come. 

We plan to continue to share updates on our continued evolution on this news page on our website. As always, feel free to reach out to your NanoString representative for more information. 


Brad Gray
President and CEO, NanoString Technologies, Inc.